News

ReAlta Life Sciences Announces Appointment of Distinguished Biopharmaceutical Leader Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of the Board

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, announced the appointment of Lewis T. “Rusty” Williams, M.D., Ph.D. as Chairman of its Board of Directors, effective immediately. Edward A. “Buzz” Heidt Jr., who has served as Chairman since 2020, will continue to serve as a member of the Board of Directors.

“We are delighted to welcome Dr. Williams as Chairman of our Board of Directors,” said David Marek, Chief Executive Officer of ReAlta. “His exceptional track record in building successful biopharmaceutical companies and expertise in drug development will be invaluable as ReAlta advances its clinical programs.”

“I would like to welcome Rusty to ReAlta at this exciting time in the company’s evolution,” said Buzz Heidt, member of ReAlta’s Board of Directors. “Rusty brings a wealth of leadership experience and insight to ReAlta, and I am eager to work with him as our incoming Board Chairman.”

“On behalf of the entire Board,” said Mr. Marek, “I wish to extend our sincerest gratitude to Buzz Heidt for over four years of Board service to ReAlta. Buzz’s collaborative partnership in the boardroom and strong leadership has positioned ReAlta for long-term success and Rusty and I look forward to his continued contributions as a Board member.”

“ReAlta is taking an innovative approach to address inflammation – the key driver of diseases across a wide spectrum of therapeutic areas. The unique ability of ReAlta’s dual-targeting EPICC peptides to address the earliest stages of the inflammatory cascade holds promise for treating inflammatory diseases successfully in ways existing therapies have been unable to,” said Dr. Williams. “I look forward to working closely with the Board Directors and management team to help realize the full potential of ReAlta’s technology to benefit patients with severe inflammatory diseases who currently have limited therapeutic options.”

Learn more here. 

Recent News

03/13/2025

Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease

Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), today announced its investment in Illexcor Therapeutics (Illexcor), a pioneering biopharmaceutical company developing next-generation oral therapies for sickle cell disease (SCD). This investment underscores Zynext Ventures’ commitment to supporting disruptive healthcare innovations that address significant unmet medical needs. Illexcor is developing

03/05/2025

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.2 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These projects were awarded in Grant Round 17. “The Catalyst works to help industry partners and academic investigators to raise follow-on

02/27/2025

Hourigan Strengthens Leadership in Advanced Manufacturing and Data Centers with Key Appointments

Hourigan is expanding its leadership team to support the firm’s growing presence in two of the region’s most technical and high-demand industries: advanced manufacturing and data centers. Hourigan has named Mark Hourigan, Jr. to lead its advanced manufacturing and logistics sector and Mark Rainey to oversee its mission-critical and data center expansion. These appointments build